Veracyte
Veracyte Q3 Revenues Nearly Double
Total revenues grew to $60.4 million and testing volume for its genomic tests were up 79 percent year over year.
The company recently presented new results on the test's sensitivity and specificity, as well as its performance across specific nodule sizes and cancer stages.
Veracyte Aims to Broaden Reach of Decipher Prostate Assay as Studies Continue to Expand Utility
Premium
The company reported significant momentum in test volumes for the second quarter of this year as new publications shore up utility evidence and open new applications.
Veracyte Q2 Revenues More Than Double on Test Volume Spike
The company's commercial test volume and test revenues were both up more than 200 percent compared to the same quarter last year.
Jun 4, 2021
Jun 1, 2021
Veracyte to Acquire HalioDx for €260M
Feb 17, 2021
Veracyte Q4 2020 Revenues Rise 16 Percent
Aug 5, 2020
Veracyte Prices $180M Public Stock Offering
Jul 30, 2020